NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.56 +0.08 (+0.10%) GOLD FUTURES
2,322.10 -9.10 (-0.39%) DOW
38,904.47 +52.20 (+0.13%) Bitcoin GBP
50,892.76 +129.66 (+0.26%)
CytomX Therapeutics, Inc. (CTMX)
| Previous close | 4.3700 |
| Open | 4.4500 |
| Bid | 4.3000 x 100 |
| Ask | 4.3400 x 100 |
| Day's range | 4.2150 - 4.4900 |
| 52-week range | 1.0400 - 5.8500 |
| Volume | |
| Avg. volume | 4,848,847 |
| Market cap | 294.354M |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
- CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study - - Management to hold conference call at 5 p.m. EDT / 2 p.m. PDT on May 8th- SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report first quarter 2024 results and provide an initial CX-904 Phase 1a dose
- GlobeNewswire
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study (NCT06265688) of CX-2051 in patients with advanced solid tumors. CX-2051 is a masked PROBODY® antibody drug conjugate (ADC) directed toward epithelial cell adhesion molecule (EpCAM), a cell-surface target that is highly expressed across ma
- GlobeNewswire
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date - - CytomX-retains US co-commercialization and economic rights for select programs - SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. today announced the achievement of a second clinical candidate nomination under the companies’ TCB collaboration with Astellas, triggering a $5 million milest
